Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
In Vitro & In Vivo Diagnostic Substances · market cap $498M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| TOCOSOL Paclitaxel | Phase 2 | Bladder Neoplasms |
| S-8184 Paclitaxel Injectable Emulsion | Phase 2 | Urologic Neoplasms |
| Cytisinicline | Phase 3 | Smoking Cessation |
| Custirsen | Phase 3 | Prostate Cancer |
| custirsen (OGX-011)/mitoxantrone | Phase 2 | Prostate Cancer |
| custirsen sodium | Phase 3 | Non-small Cell Lung Cancer |
| Cytisine | Phase 2 | Smoking Cessation |
| cabazitaxel | Phase 3 | Prostate Cancer |
| OGX-427 600 mg | Phase 2 | Urologic Neoplasms |
| TOCOSOL(R) Paclitaxel | Phase 2 | Breast Cancer |
| Docetaxel | Phase 3 | Non-Small Cell Lung Cancer |
Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.